The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Orally available compound prevents deficits in memory caused by the Alzheimer amyloid‐β oligomers
Abstract
Objective: Despite progress in defining a pathogenic role for amyloid β protein (Aβ) in Alzheimer's disease, orally bioavailable compounds that prevent its effects on hippocampal synaptic plasticity and cognitive function have not yet emerged. A particularly attractive therapeutic strategy is to selectively neutralize small, soluble Aβ oligomers that have recently been shown to mediate synaptic dysfunction. Methods: Using electrophysiological, biochemical, and behavioral assays, we studied how scyllo‐inositol (AZD‐103; molecular weight, 180) neutralizes the acutely toxic effects of Aβ on synaptic function and memory recall. Results: Scyllo‐inositol, but not its stereoisomer, chiro‐inositol, dose‐dependently rescued long‐term potentiation in mouse hippocampus from the inhibitory effects of soluble oligomers of cell‐derived human Aβ. Cerebroventricular injection into rats of the soluble Aβ oligomers interfered with learned performance on a complex lever‐pressing task, but administration of scyllo‐inositol via the drinking water fully prevented oligomer‐induced errors. Interpretation: A small, orally available natural product penetrates into the brain in vivo to rescue the memory impairment produced by soluble Aβ oligomers through a mechanism that restores hippocampal synaptic plasticity. Ann Neurol 2006;60:668–676
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Self-citationWalsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Self-citationDeciphering the Molecular Basis of Memory Failure in Alzheimer's Disease
Walsh, D. M., & Selkoe, D. J. (2004) · Neuron · doi:10.1016/j.neuron.2004.09.010 · Cited by 1,207
Self-citationAmyloid β protein immunotherapy neutralizes Aβ oligomers that disrupt synaptic plasticity in vivo
Klyubin, I., Walsh, D. M., Lemere, C. A., Cullen, W. K., Shankar, G. M., Betts, V., Spooner, E. T., Jiang, L., Anwyl, R., Selkoe, D. J., et al. (2005) · Nature Medicine · doi:10.1038/nm1234 · Cited by 489
Self-citation
Cited by
Aβ Oligomers – a decade of discovery
Walsh, D. M., & Selkoe, D. J. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04426.x · Cited by 1,938
Self-citationShankar, G. M., Bloodgood, B. L., Townsend, M., Walsh, D. M., Selkoe, D. J., & Sabatini, B. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4970-06.2007 · Cited by 1,592
Self-citationEmmanouilidou, E., Melachroinou, K., Roumeliotis, T., Garbis, S. D., Ntzouni, M., Margaritis, L. H., Stefanis, L., & Vekrellis, K. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5699-09.2010 · Cited by 1,115
“SI, a cellpermeable sugar, can successfully neutralize the adverse effects of A oligomeric species, possibly by stabilizing a nontoxic conformation of A oligomers (McLaurin et al., 2000; Townsend et al., 2006).”
BackgroundA critical appraisal of amyloid-β-targeting therapies for Alzheimer disease
Panza, F., Lozupone, M., Logroscino, G., & Imbimbo, B. P. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0116-6 · Cited by 965
Alzheimer's Disease: From Pathology to Therapeutic Approaches
Jakob‐Roetne, R., & Jacobsen, H. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200802808 · Cited by 626
Metadata
- Authors
- Townsend, M., Cleary, J. P., Mehta, T., Hofmeister, J., Lesne, S., O'Hare, E., Walsh, D. M., & Selkoe, D. J.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2006-12
- Volume
- 60
- Issue
- 6
- Pages
- 668-676
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2050529442
- Cited by
- 167
- References
- 4
- FWCI
- 9.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Orally available compound prevents deficits in memory caused by the Alzheimer amyloid‐β oligomers. https://app.cochat.ai/papers/10.1002/ana.21051
- The paper
- Townsend, M., Cleary, J. P., Mehta, T., Hofmeister, J., Lesne, S., O'Hare, E., Walsh, D. M., & Selkoe, D. J. (2006). Orally available compound prevents deficits in memory caused by the Alzheimer amyloid‐β oligomers. Annals of Neurology. https://doi.org/10.1002/ana.21051
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.